LXH254
Total Payments
$2.2M
Transactions
18
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.3M | 10 | 1 |
| 2019 | $675,335 | 5 | 0 |
| 2017 | $190,737 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 18 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE IB OPEN LABEL MULTICENTER STUDY OF ORAL LXH254 IN COMBINATION WITH ORAL LTT462 IN ADULT PATIENTS WITH ADVANCED OR METASTATIC KRAS OR BRAF MUTANT NON SMALL CELL LUNG CANCER | Novartis Pharmaceuticals Corporation | $1.7M | 0 |
| A PHASE I DOSE FINDING STUDY OF ORAL LXH254 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING MAPK PATHWAY ALTERATIONS | Novartis Pharmaceuticals Corporation | $277,557 | 0 |
| A RANDOMIZED, OPEN-LABEL, MULTI-ARM, TWO-PART, PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF MULTIPLE LXH254 COMBINATIONS IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC BRAFV600 OR NRAS MUTANT MELANOMA | Novartis Pharmaceuticals Corporation | $175,690 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $238.00 | 1 |
Top Doctors Receiving Payments for LXH254
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $2.2M | 17 |
| , MD MPH | Medical Oncology | Boston, MA | $238.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.2M
- Total Doctors 1
- Transactions 18
About LXH254
LXH254 is a drug associated with $2.2M in payments to 1 healthcare providers, recorded across 18 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $1.3M was paid across 10 transactions to 1 doctors.
The most common payment nature for LXH254 is "Unspecified" ($2.2M, 100.0% of total).
LXH254 is associated with 4 research studies, including "A PHASE IB OPEN LABEL MULTICENTER STUDY OF ORAL LXH254 IN COMBINATION WITH ORAL LTT462 IN ADULT PATIENTS WITH ADVANCED OR METASTATIC KRAS OR BRAF MUTANT NON SMALL CELL LUNG CANCER" ($1.7M).